DVL1 (Dishevelled Segment Polarity Protein 1) is a key cytoplasmic effector of the Wnt signaling pathway that plays critical roles in embryonic development, neuronal differentiation, synapse formation, and adult brain function. As a central component of both canonical (β-catenin-dependent) and non-canonical Wnt pathways, DVL1 integrates extracellular Wnt signals to regulate gene transcription, cytoskeletal dynamics, and cell-cell communication. Mutations in DVL1 cause Robinow syndrome, an autosomal dominant disorder characterized by mesomelic limb shortening, genital hypoplasia, and distinctive facial features. Additionally, dysregulated DVL1 signaling has been implicated in Alzheimer's disease, Parkinson's disease, and autism spectrum disorders [1][2].
.infobox.infix-gene
; Gene Symbol
: DVL1
; Full Name
: Dishevelled Segment Polarity Protein 1
; Chromosomal Location
: 1p36.33
; NCBI Gene ID
: 1855
; OMIM
: 604360
; Ensembl ID
: ENSG00000107485
; UniProt ID
: Q92997
; Associated Diseases
: Alzheimer's Disease, Autism Spectrum Disorder, Robinow Syndrome
DVL1 encodes a member of the Dishevelled (DVL) protein family, which are key components of the Wnt signaling pathway. DVL1 acts as a positive regulator of canonical Wnt signaling by antagonizing beta-catenin degradation. In neurons, DVL1 localizes to synapses and regulates synaptic formation and function. DVL1 mutations cause Robinow syndrome, an autosomal dominant genetic disorder. Dysregulated DVL1 signaling has been implicated in Alzheimer's disease and autism spectrum disorders.
The DVL1 protein contains several conserved domains that mediate protein-protein interactions and signal transduction:
The DIX domain (approximately 80 amino acids) mediates DVL1 self-association and polymerization, which is essential for signal transduction. This domain allows DVL1 to form cytoplasmic puncta in response to Wnt stimulation [3].
The PDZ domain (approximately 90 amino acids) binds to the C-terminal motif of transmembrane receptors and scaffolding proteins, including:
The DEP domain (approximately 80 amino acids) is required for:
This region contains binding sites for SH3 domain-containing proteins and participates in cytoskeletal regulation.
In the canonical Wnt pathway, DVL1 acts downstream of Frizzled receptors to inhibit the β-catenin destruction complex (containing GSK3β, APC, Axin, and CK1α). Upon Wnt ligand binding:
DVL1 also participates in β-catenin-independent pathways:
Planar Cell Polarity (PCP) Pathway
Wnt/Ca²⁺ Pathway
DVL1 localizes to both pre- and post-synaptic compartments where it:
DVL1 is widely expressed in the developing and adult brain:
Developmental Expression
Adult Brain Expression
Heterozygous missense mutations in DVL1 cause autosomal dominant Robinow syndrome, characterized by:
The pathogenic mechanisms involve:
Multiple lines of evidence link DVL1 to Alzheimer's disease pathogenesis:
Amyloid-Beta (Aβ) Regulation
Tau Pathology
Synaptic Dysfunction
DVL1 is implicated in autism spectrum disorders through:
While not a neurodegenerative disease, DVL1 dysregulation is observed in various cancers:
Targeting DVL1 and the Wnt pathway for neurodegeneration:
DVL1 expression changes may serve as:
Ongoing research focuses on:
The study of Dvl1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. DOI:10.1146/annurev.cellbio.20.010403.113126
MacDonald BT, Tamai K, He X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9-26. DOI:10.1016/j.devcel.2009.06.016
Schwarz-Romond T, Fiedler M, Shibata N, et al. The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization. Nat Struct Mol Biol. 2007;14(6):484-492. DOI:10.1038/nsmb1247
Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149(6):1192-1205. DOI:10.1016/j.cell.2012.05.012
Avila ME, Sepúlveda FJ, Burgos CF, et al. WNT signaling at the synapse: implications for Alzheimer's disease. Neurobiol Dis. 2020;142:104970. DOI:10.1016/j.nbd.2020.104970
White J, Mazzeu JF, Hoischen A, et al. DVL1 frameshift mutations, in contrast to loss-of-function mutations, may cause a Robinow syndrome-like phenotype. Am J Hum Genet. 2015;97(3):400-406. DOI:10.1016/j.ajhg.2015.06.014
Liu C, Wu D, Xia M, et al. Functional analysis of DVL1 mutations causing Robinow syndrome. J Hum Genet. 2018;63(4):497-505. DOI:10.1038/s10038-017-0354-0
Inestrosa NC, Varela-Nallar L. Wnt signaling in the nervous system: from synaptic plasticity to neurodegeneration. Biocell. 2014;38(3):145-150.
Cardozo T, Pagano M. The Axin at the intersection of Wnt and E3 ubiquitin ligase pathways. Trends Cell Biol. 2009;19(1):1-3. DOI:10.1016/j.tcb.2008.11.002
Mineur YS, Tchenio A, Harland J, et al. Interaction between brain Wnt signaling and behavior: role of social isolation. Behav Brain Res. 2017;322(Pt B):280-288. DOI:10.1016/j.bbr.2016.07.025
Zhang X, Tian Y, Li Z, et al. Discovery and optimization of small molecules targeting Wnt signaling for the treatment of neurodegenerative diseases. J Med Chem. 2019;62(8):3917-3932. DOI:10.1021/acs.jmedchem.8b01894